素通过与肝脏核因子4α的同活化促进肝脏葡萄糖生成和葡萄糖代谢
Xiaomin Luo1, Fang Liu1, Lijun Zhu2
1Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Molecular metabolism
|November 27, 2024
概括
素 (LPXN) 是一种新型的HNF4α联合激活剂,可以调节肝脏葡萄糖生成. 向LPXN可能为治疗2型糖尿病和代谢障碍提供新的治疗策略.
科学领域:
- 代谢调节 代谢调节 代谢调节
- 分子内分泌学分子内分泌学
- 肝脏生理学 肝脏生理学
背景情况:
- 肝脏葡萄糖生成对于维持血糖平衡至关重要.
- 失调的葡萄糖生成有助于高血糖症,2型糖尿病 (T2D) 和代谢障碍.
- 肝核因子-4α (HNF4α) 是葡萄糖生成的关键调节者.
研究的目的:
- 为了确定参与肝脏葡萄糖生成的HNF4α的新型协活性剂.
- 为了研究素 (LPXN) 在调节葡萄糖代谢中的作用.
- 探索LPXN作为糖尿病治疗点的潜力.
主要方法:
- 蛋白质拉下测试,质谱和光酶测试确定了LPXN作为HNF4α联合激活剂.
- 在体内和体外研究中,在小鼠模型 (ob/db/DIO) 和细胞培养物 (HepG2,初级肝细胞) 中使用了腺病毒介导的过度表达和shRNA介导的淘汰.
- CUT&Tag和ChIP-qPCR阐明了LPXN的作用机制,包括通过Gcg-cAMP-PKA通路进行核转位和PEPCK促进体结合. 分析了人类肝脏组织的翻译相关性.
主要成果:
- LPXN与HNF4α相互作用,并在肝脏葡萄糖生成中发挥关键作用.
- LPXN 敲击增强了葡萄糖代谢,而过度表达则抑制了它.
- LPXN通过与PEPCK促进体结合来调节葡萄糖生成,主要通过Gcg-cAMP-PKA通路. 在肥胖症和糖尿病患者中观察到LPXN表达的增加.
结论:
- LPXN是肝脏葡萄糖生成的新型和关键调节剂.
- LPXN在调节葡萄糖代谢中的作用突显了其在糖尿病和代谢障碍中的病理参与.
- 准LPXN为治疗糖尿病和相关代谢疾病提供了一个有希望的治疗途径.
相关概念视频
cAMP-dependent Protein Kinase Pathways
6.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.1K
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Cell Specific Gene Expression
13.5K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.5K
GPCRs Regulate Adenylyl Cylase Activity
5.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171


